FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080456473> ?p ?o ?g. }

• W3080456473 endingPage "110596" @default.
• W3080456473 startingPage "110596" @default.
• W3080456473 abstract "Sacubitril/valsartan, the first agent to be approved in a new class of drugs called angiotensin receptor neprilysin inhibitors (ARNIs), has been shown to reduce cardiovascular mortality and morbidity compared to enalapril in outpatient subjects with chronic heart failure (HF) and reduced left ventricular ejection fraction (HFrEF). However, there is little real-world evidence about the efficacy of ARNIs in elderly hypertensive patients with HFrEF and comorbidities.In this prospective open-label study, 108 subjects, 54 of them (mean age 78.6 ± 8.2 years, 75.0 % male), with HFrEF (29.8 ± 4.3 %) and New York Heart Association (NYHA) class II-III symptoms were assigned to receive ARNIs twice daily, according to the recommended dosage of 24/26, 49/51, 97/103 mg. Patients were gender- and age-matched with a control arm of patients with HFrEF receiving the optimal standard therapy for HF. The clinic blood pressure (BP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), estimated glomerular filtration rate (eGFR), blood glucose and glycated hemoglobin (HbA1c), uric acid (UA), left ventricular ejection fraction (LVEF) and NYHA class were evaluated at a mean follow-up of 12 months. During the follow-up, the clinical outcomes, including mortality and re-hospitalization for HF, were collected.NYHA class significantly improved in the ARNI arm compared to the control (24.9 vs. 6.4 %, shifting from class III to II, and 55.4 vs. 25.2 %, from class II to I, p < 0.05 for all). A significant improvement in LVEF and eGFR levels was found in the ARNI arm compared to controls (42.4 vs. 34.2 %, 73.8 vs. 61.2 mL/min, respectively; p < 0.001 for all). NT-proBNP, clinic systolic and diastolic BP, blood glucose, HbA1c and UA values were reduced in both treatment arms, but they were lower in the ARNI arm compared controls (3107 vs. 4552 pg/mL, 112.2 vs. 120.4 and 68.8 vs. 75.6 mmHg, 108.4 vs. 112.6 mg/dL, 5.4 vs. 5.9 % and 5.9 vs. 6.4 mg/dL, respectively, p < 0.05). Mortality and re-hospitalization for HF was lower in the ARNI arm than controls (20.1 vs. 33.6 % and 27.7 vs. 46.3 % respectively; p < 0.05 for all). Gender differences were not found in either arm. No patients refused to continue the study, and no side effects to the ARNI treatment were observed.In elderly patients with HFrEF and comorbidities, ARNI treatment seems effective and safe. The improvement in LVEF and cardiac remodeling, BP, eGFR, serum glucose, UA and HbA1c could be the mechanisms by which ARNIs play their beneficial role on clinical outcomes. However, these results need to be confirmed in studies involving a greater number of subjects, and with a longer follow-up." @default.
• W3080456473 created "2020-09-01" @default.
• W3080456473 creator A5000545163 @default.
• W3080456473 creator A5001609991 @default.
• W3080456473 creator A5007949435 @default.
• W3080456473 creator A5019805224 @default.
• W3080456473 creator A5026008599 @default.
• W3080456473 creator A5059462029 @default.
• W3080456473 creator A5063876619 @default.
• W3080456473 creator A5072296038 @default.
• W3080456473 creator A5089202679 @default.
• W3080456473 date "2020-10-01" @default.
• W3080456473 modified "2023-10-18" @default.
• W3080456473 title "The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings" @default.
• W3080456473 cites W1141258917 @default.
• W3080456473 cites W1500963439 @default.
• W3080456473 cites W1862226808 @default.
• W3080456473 cites W1962897728 @default.
• W3080456473 cites W1971443332 @default.
• W3080456473 cites W1977483151 @default.
• W3080456473 cites W1978002425 @default.
• W3080456473 cites W1993606481 @default.
• W3080456473 cites W1995426124 @default.
• W3080456473 cites W1995934832 @default.
• W3080456473 cites W2024196604 @default.
• W3080456473 cites W2024908020 @default.
• W3080456473 cites W2026862257 @default.
• W3080456473 cites W2028770910 @default.
• W3080456473 cites W2030649527 @default.
• W3080456473 cites W2035400847 @default.
• W3080456473 cites W2035788322 @default.
• W3080456473 cites W2046240540 @default.
• W3080456473 cites W2050203512 @default.
• W3080456473 cites W2054188240 @default.
• W3080456473 cites W2056893352 @default.
• W3080456473 cites W2058192044 @default.
• W3080456473 cites W2066889226 @default.
• W3080456473 cites W2081861176 @default.
• W3080456473 cites W2083565359 @default.
• W3080456473 cites W2092003450 @default.
• W3080456473 cites W2093934591 @default.
• W3080456473 cites W2094612556 @default.
• W3080456473 cites W2096073058 @default.
• W3080456473 cites W2098833615 @default.
• W3080456473 cites W2113698123 @default.
• W3080456473 cites W2154103386 @default.
• W3080456473 cites W2166524899 @default.
• W3080456473 cites W2172032309 @default.
• W3080456473 cites W2224556300 @default.
• W3080456473 cites W2283093578 @default.
• W3080456473 cites W2341033088 @default.
• W3080456473 cites W2407303033 @default.
• W3080456473 cites W2413467082 @default.
• W3080456473 cites W2427094903 @default.
• W3080456473 cites W2440694817 @default.
• W3080456473 cites W2465374486 @default.
• W3080456473 cites W2468387939 @default.
• W3080456473 cites W2470693201 @default.
• W3080456473 cites W2475261460 @default.
• W3080456473 cites W2522023618 @default.
• W3080456473 cites W2556091951 @default.
• W3080456473 cites W2560321248 @default.
• W3080456473 cites W2564213835 @default.
• W3080456473 cites W2595010755 @default.
• W3080456473 cites W2605361667 @default.
• W3080456473 cites W2606568709 @default.
• W3080456473 cites W2611066427 @default.
• W3080456473 cites W2621590079 @default.
• W3080456473 cites W2623434376 @default.
• W3080456473 cites W2766372172 @default.
• W3080456473 cites W2773999918 @default.
• W3080456473 cites W2791015597 @default.
• W3080456473 cites W2794519283 @default.
• W3080456473 cites W2794823537 @default.
• W3080456473 cites W2797845698 @default.
• W3080456473 cites W2808897169 @default.
• W3080456473 cites W2810048348 @default.
• W3080456473 cites W2823437001 @default.
• W3080456473 cites W2913997068 @default.
• W3080456473 cites W2918599246 @default.
• W3080456473 cites W2948010547 @default.
• W3080456473 cites W2982651646 @default.
• W3080456473 cites W82015992 @default.
• W3080456473 cites W2604870649 @default.
• W3080456473 doi "https://doi.org/10.1016/j.biopha.2020.110596" @default.
• W3080456473 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34321170" @default.
• W3080456473 hasPublicationYear "2020" @default.
• W3080456473 type Work @default.
• W3080456473 sameAs 3080456473 @default.
• W3080456473 citedByCount "14" @default.
• W3080456473 countsByYear W30804564732021 @default.
• W3080456473 countsByYear W30804564732022 @default.
• W3080456473 countsByYear W30804564732023 @default.
• W3080456473 crossrefType "journal-article" @default.
• W3080456473 hasAuthorship W3080456473A5000545163 @default.
• W3080456473 hasAuthorship W3080456473A5001609991 @default.
• W3080456473 hasAuthorship W3080456473A5007949435 @default.
• W3080456473 hasAuthorship W3080456473A5019805224 @default.

• next